Clinical Trials Browser

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT03937830 2026-03-24

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Phase 2 Active not recruiting

27 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06040099 2026-03-19

EMERALD-Y90

Phase 2 Active not recruiting

58 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03847428 2026-03-06

EMERALD-2

Phase 3 Active not recruiting

908 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06608940 2026-02-19

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Phase 1/2 Withdrawn

Gastrointestinal

Liver Neoplasms

NCT05883644 2026-02-18

SIERRA

Phase 3 Active not recruiting

111 enrolled

Gastrointestinal

Liver Neoplasms

NCT05155189 2026-01-21

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Phase 1 Recruiting

72 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07226063 2025-11-10

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

Phase 2 Not yet recruiting

16 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05701488 2025-09-02

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Phase 1 Recruiting

20 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05451043 2025-06-26

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Phase 2 Recruiting

62 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma